Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2023 |
Jun. 21, 2023 |
Dec. 31, 2022 |
Feb. 25, 2019 |
|
| Fair Value Measurements | |||||
| Changes in estimated fair value of contingent consideration | $ 75 | ||||
| Contingent consideration under RPAs, AAAs and CPPAs | $ 4,000 | 4,000 | $ 75 | ||
| Bioasis | Royalty Purchase Agreement | |||||
| Fair Value Measurements | |||||
| Contingent consideration under RPAs, AAAs and CPPAs | 0 | $ 0 | $ 75 | $ 75 | |
| LadRx | Royalty Purchase Agreement | |||||
| Fair Value Measurements | |||||
| Changes in estimated fair value of contingent consideration | $ 0 | ||||
| Contingent consideration under RPAs, AAAs and CPPAs | $ 1,000 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|